Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 10 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2021 Filed Aug 16, 2021 21:14 UTC Amendment |
FMR LLC10% owner · See Remark 1
|
OtherCommon Stock | 7,454 | $0.00 | $0.00 |
DisclosureSEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP Disclosed balance after: 0 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document |
| August 06, 2021 Filed Aug 16, 2021 21:14 UTC Amendment |
FMR LLC10% owner · See Remark 1
|
OtherCommon Stock | 7,454 | $0.00 | $0.00 |
DisclosureSEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Advisors Fund V LP Disclosed balance after: 7,454 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document |
| August 06, 2021 Filed Aug 16, 2021 21:14 UTC Amendment |
FMR LLC10% owner · See Remark 1
|
OtherCommon Stock | 745,393 | $0.00 | $0.00 |
DisclosureSEC source: 0000315066-21-001702 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · F-Prime Capital Partners Healthcare Fund V LP Disclosed balance after: 6,226,519 F1 · ownership.nature: These holdings were acquired or disposed of (as applicable) in the form of a distribution without payment of consideration. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
Exercise / conversionStock Option (Right to Buy · Derivative | 25,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · derivative · entry 16 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,345 Underlying: Common Stock · 25,000 shares Expires 2028-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, January 8, 2018, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 2,250 | $112.62 | $253,395.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 14 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,525 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $112.00 to $112.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 3,456 | $111.51 | $385,378.56 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 13 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,023,775 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $111.04 to $111.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 3,982 | $110.54 | $440,170.28 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 12 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,231 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $110.04 to $110.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 4,800 | $109.58 | $525,984.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 11 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,213 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $109.01 to $109.98, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 800 | $108.65 | $86,920.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 10 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,013 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $108.32 to $108.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 167 | $107.31 | $17,920.77 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 9 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,813 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $107.29 to $107.33, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 500 | $106.48 | $53,240.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 8 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,036,980 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $106.12 to $106.77, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 1,800 | $105.44 | $189,792.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 7 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,480 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $105.02 to $105.98, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 1,336 | $104.40 | $139,478.40 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 6 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,039,280 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $104.00 to $104.96, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 2,864 | $103.52 | $296,481.28 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 5 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,040,616 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $103.21 to $103.96, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 100 | $102.00 | $10,200.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 4 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,480 Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 2,300 | $101.27 | $232,921.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 3 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,043,580 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $101.00 to $101.85, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
SaleCommon Stock | 645 | $100.69 | $64,945.05 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 2 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,045,880 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $100.25 to $100.99, inclusive. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 22:00 UTC |
Evans John M.Director · CEO
|
Exercise / conversionCommon Stock | 25,000 | $1.03 | $25,750.00 |
DisclosureSEC source: 0000899243-21-027903 · doc4.xml · nonDerivative · entry 1 Evans John M. · CIK 0001786304 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,614 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · derivative · entry 14 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,561 Underlying: Common Stock · 2,614 shares Expires 2030-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F11 · derivative.exercise_date: The option vests as to one third on the first anniversary of the of the vesting commencement date, February 5, 2020, and at a rate of 4.17% each month thereafter until the option is fully vested. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 100 | $129.38 | $12,938.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 13 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 100 | $128.67 | $12,867.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 12 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 100 | $126.51 | $12,651.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 11 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 300 | $124.31 | $37,293.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 10 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.28 to $124.33, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 200 | $123.76 | $24,752.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 9 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.64 to $123.88, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 100 | $122.85 | $12,285.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 8 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 400 | $121.59 | $48,636.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 7 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.19 to $121.96, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 200 | $120.39 | $24,078.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 6 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.37 to $120.40, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 100 | $119.68 | $11,968.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 5 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.67 to $119.68, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 200 | $118.35 | $23,670.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 4 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.00 to $118.71, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 200 | $116.41 | $23,282.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 3 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.13 to $116.69, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
SaleCommon Stock | 614 | $115.38 | $70,843.32 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 2 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.04 to $115.88, inclusive. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 22:00 UTC |
COOPER GRAHAM KDirector
|
Exercise / conversionCommon Stock | 2,614 | $17.00 | $44,438.00 |
DisclosureSEC source: 0000899243-21-027902 · doc4.xml · nonDerivative · entry 1 COOPER GRAHAM K · CIK 0001396943 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 22:01 UTC | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0000899243-21-027313 · doc4.xml · derivative · entry 4 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,941 Underlying: Common Stock · 30,000 shares Expires 2029-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. F3 · derivative.exercise_date: The option vests as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested. Read SEC document |
|
| June 30, 2021 Filed Jul 2, 2021 22:01 UTC | SaleCommon Stock | 15,000 | $127.00 | $1,905,000.00 |
DisclosureSEC source: 0000899243-21-027313 · doc4.xml · nonDerivative · entry 3 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,809 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
|
| June 30, 2021 Filed Jul 2, 2021 22:01 UTC | SaleCommon Stock | 15,000 | $117.00 | $1,755,000.00 |
DisclosureSEC source: 0000899243-21-027313 · doc4.xml · nonDerivative · entry 2 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,809 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
|
| June 30, 2021 Filed Jul 2, 2021 22:01 UTC | Exercise / conversionCommon Stock | 30,000 | $13.68 | $410,400.00 |
DisclosureSEC source: 0000899243-21-027313 · doc4.xml · nonDerivative · entry 1 Burrell Terry-Ann · CIK 0001786484 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
|
| June 30, 2021 Filed Jul 2, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 2,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006294 · form4.xml · nonDerivative · entry 3 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,067 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006294 · form4.xml · nonDerivative · entry 2 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,921,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by Overage GPLP. The Reporting Person has an interest in the Overage GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006294 · form4.xml · nonDerivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,921,520 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. The Reporting Person has an interest in the GPLP and the GPLLC but does not have voting or investment control over the shares held by ARCH IX. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:19 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 4,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006293 · form4.xml · nonDerivative · entry 5 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,111 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · ownership.direct: Shares held directly by Nelsen. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:19 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006293 · form4.xml · nonDerivative · entry 4 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,867 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:19 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 2,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006293 · form4.xml · nonDerivative · entry 3 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,328 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:19 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006293 · form4.xml · nonDerivative · entry 2 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,921,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 21:19 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006293 · form4.xml · nonDerivative · entry 1 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,921,520 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 4,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 10 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,425 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F7 · ownership.direct: Shares held directly by Nelsen. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 811 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 9 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,056 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F6 · ownership.direct: Shares held directly by Bybee. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 2,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 8 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,773 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. F5 · ownership.direct: Shares held directly by Crandell. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 7 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,121,519 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F3 · ownership.nature: These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:22 UTC |
ARCH Venture Partners IX, LLC10% owner
ARCH Venture Partners IX, L.P.10% owner
ARCH Venture Fund IX, L.P.10% owner
ARCH Venture Fund IX Overage, L.P.10% owner
CRANDELL KEITH10% owner
BYBEE CLINTON10% owner
NELSEN ROBERT10% owner
|
OtherCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006092 · form4.xml · nonDerivative · entry 6 ARCH Venture Partners IX, LLC · CIK 0001723174 · 10% owner ARCH Venture Partners IX, L.P. · CIK 0001723173 · 10% owner ARCH Venture Partners IX Overage, L.P. · CIK 0001723172 · 10% owner ARCH Venture Fund IX, L.P. · CIK 0001666306 · 10% owner ARCH Venture Fund IX Overage, L.P. · CIK 0001666307 · 10% owner CRANDELL KEITH · CIK 0001219039 · 10% owner BYBEE CLINTON · CIK 0001219043 · 10% owner NELSEN ROBERT · CIK 0001219042 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,121,520 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F2 · ownership.nature: These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| June 29, 2021 Filed Jun 29, 2021 21:20 UTC |
Burow KristinaDirector
|
OtherCommon Stock | 2,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-006091 · form4.xml · nonDerivative · entry 6 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,056 F1 · kind: Distribution of Common Stock held by a limited partnership to its partners for no consideration. F4 · kind: Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.